Koji Shinozaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Koji Shinozaki has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Ai Hashimoto
Minase Research Institute, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
1 shared publicationAkiteru Seki
Ono Pharmaceutical Co., Ltd., Japan
1 shared publicationAkito Kakuuchi
Minase Research Institute, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
1 shared publication- Atsushi Naganawa
Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
1 shared publication - Haruto Kurata
Drug Discovery Chemistry, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
1 shared publication Hiroshi Yamamoto
Minase Research Institute, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan
1 shared publication
Latest Publications
- Open Access
- 1 December 2021
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 379 (3) , 400-408
Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone–Inhibitory Effect of Octreotide after Growth Hormone–Releasing Hormone Stimulation
Acromegaly is a chronic systemic disease characterized by facial and peripheral changes caused by soft tissue overgrowth, together with multiple complications. Despite available surgical and medical therapies, suitable treatments for acromegaly are still lacking. Efficient drug development requires an understanding of the exposure-response (E-R) relationship based on non-clinical and early clinical studies. We aimed to establish a platform to facilitate the development of novel drugs to treat acromegaly. We evaluated the E-R relationship of the growth hormone (GH)-inhibitory effect of the somatostatin analogue, octreotide, under growth hormone-releasing hormone (GHRH) + arginine stimulation in healthy participants and compared the results with historical data for patients with acromegaly. This randomized five-way crossover study included two placebo and three active-treatment periods with different doses of octreotide acetate. GH secretion in the two placebo periods was comparable, confirming the reproducibility of the response with no carryover effect. GH secretion was inhibited by low-, medium-, and high-dose octreotide acetate, in a dose-dependent manner. We also examined the E-R relationship in monkeys as a preclinical drug evaluation study and in rats as a more convenient and simple system for screening candidate drugs. The E-R relationships and EC50 values were similar among animals, healthy paticipants and patients with acromegaly, which suggests that GH stimulation studies in early research and development stages allowed simulation of the drug responses in patients with acromegaly. Significance Statement We demonstrated similar exposure–response relationships in terms of the growth hormone-inhibitory effect of octreotide following growth hormone-releasing hormone stimulation among healthy participants, monkeys, and rats. The research methods and analyses utilized in this study will be useful for simulating the dosages and therapeutic effects of drugs for acromegaly, and will facilitate the research and development of novel therapeutic agents with similar modes of action.
- 1 December 2021
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 379 (3) , 400-408
Open AccessNovel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone–Inhibitory Effect of Octreotide after Growth Hormone–Releasing Hormone Stimulation
Acromegaly is a chronic systemic disease characterized by facial and peripheral changes caused by soft tissue overgrowth, together with multiple complications. Despite available surgical and medical therapies, suitable treatments for acromegaly are still lacking. Efficient drug development requires an understanding of the exposure-response (E-R) relationship based on non-clinical and early clinical studies. We aimed to establish a platform to facilitate the development of novel drugs to treat acromegaly. We evaluated the E-R relationship of the growth hormone (GH)-inhibitory effect of the somatostatin analogue, octreotide, under growth hormone-releasing hormone (GHRH) + arginine stimulation in healthy participants and compared the results with historical data for patients with acromegaly. This randomized five-way crossover study included two placebo and three active-treatment periods with different doses of octreotide acetate. GH secretion in the two placebo periods was comparable, confirming the reproducibility of the response with no carryover effect. GH secretion was inhibited by low-, medium-, and high-dose octreotide acetate, in a dose-dependent manner. We also examined the E-R relationship in monkeys as a preclinical drug evaluation study and in rats as a more convenient and simple system for screening candidate drugs. The E-R relationships and EC50 values were similar among animals, healthy paticipants and patients with acromegaly, which suggests that GH stimulation studies in early research and development stages allowed simulation of the drug responses in patients with acromegaly. Significance Statement We demonstrated similar exposure–response relationships in terms of the growth hormone-inhibitory effect of octreotide following growth hormone-releasing hormone stimulation among healthy participants, monkeys, and rats. The research methods and analyses utilized in this study will be useful for simulating the dosages and therapeutic effects of drugs for acromegaly, and will facilitate the research and development of novel therapeutic agents with similar modes of action.
- 1 February 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (4) , 1209-1213
Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives
- 1 February 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (4) , 1209-1213
Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives